Search results
22 mar 2023 · Active TB disease may be treated for four, six or nine months. Specialists in TB treatment will determine which drugs are best for you. You will have regular appointments to see if you're improving and to watch for side effects.
- Tuberculosis-Tuberculosis
Si usted es un paciente de Mayo Clinic, esto puede incluir...
- Doctors & Departments
Learn about the prevention and treatment of this disease...
- Tuberculosis
A person taking drugs to treat active TB disease usually...
- Tuberculosis-Tuberculosis
22 mar 2023 · A person taking drugs to treat active TB disease usually can't pass the disease after 2 to 3 weeks of treatment. Drug-resistant TB Some forms of the TB bacteria have become drug resistant.
The four new recommendations concern drug-susceptible TB (DS-TB): (i) a four-month regimen for children and adolescents below 16 years of age with non-severe drug-susceptible TB (section 5.1); (ii) a six-month intensive regimen to treat TBM composed of isoniazid, rifampicin, pyrazinamide and ethionamide (section 5.2); (iii) use of bedaquiline ...
For the treatment of TB in pregnant women, the initial regimen should be INH, RIF, and EMB for at least 9 months. Although teratogenicity data for PZA are limited, it is probably safe to use in pregnancy. Breast-feeding should not be discouraged for women receiving anti-TB treatment.
1 gru 2021 · There are now several effective and safe regimens for the treatment of TBI in children. For improved adherence to therapy, the 3 rifamycin-based regimens are preferred because of their short duration. Daily isoniazid can be used if there is intolerance or drug interactions with rifamycins.
Pediatric multidrug-resistant tuberculosis (MDR-TB) remains a significant global problem, and there are numerous barriers preventing children with MDR-TB from being identified, confirmed with microbiologic tests, and treated with a safe, practical, and effective regimen.
Mayo Clinic Center for Tuberculosis is dedicated to the global effort of eliminating tuberculosis by 2030. Our center supports TB program development, education, training, and research for healthcare professionals and public service providers across our region.
